PHASE-2 TRIAL OF CYTEMBENA IN PATIENTS WITH ADVANCED OVARIAN AND BREAST-CANCER

  • 1 January 1976
    • journal article
    • research article
    • Vol. 60  (11) , 1655-1658
Abstract
Thirty women with histologically proven advanced ovarian or breast cancer were treated with cytembena. Of 9 patients with ovarian cancer and 21 with breast cancer none had worthwhile objective remissions. Cytembena was given at a dose of 250 mg/m2 per day for a course of 5 days repeated at weekly intervals. Improvement, particularly relief of pain from skeletal metastases, was observed in 16 patients. An additional 7 patients had stable disease while treated with cytembena. Cytembena has no hemopoietic toxicity, but nausea and vomiting and an autonomic storm phenomenon are dose limiting factors. Further studies incorporating this drug in combination regimens seem warranted.